Cetera Advisors LLC Has $1.09 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Cetera Advisors LLC grew its position in shares of Edwards Lifesciences Co. (NYSE:EWGet Rating) by 10.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,448 shares of the medical research company’s stock after acquiring an additional 1,084 shares during the quarter. Cetera Advisors LLC’s holdings in Edwards Lifesciences were worth $1,089,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Lazard Asset Management LLC raised its stake in shares of Edwards Lifesciences by 680.2% during the 2nd quarter. Lazard Asset Management LLC now owns 50,916 shares of the medical research company’s stock worth $4,840,000 after purchasing an additional 44,390 shares in the last quarter. GW&K Investment Management LLC bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $127,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Edwards Lifesciences by 12.2% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 50,075 shares of the medical research company’s stock worth $5,894,000 after purchasing an additional 5,441 shares in the last quarter. J.W. Cole Advisors Inc. raised its stake in shares of Edwards Lifesciences by 4.7% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 3,521 shares of the medical research company’s stock worth $335,000 after purchasing an additional 157 shares in the last quarter. Finally, Moody National Bank Trust Division bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $621,000. Institutional investors and hedge funds own 81.33% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, CEO Michael A. Mussallem sold 19,875 shares of the business’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $84.17, for a total transaction of $1,672,878.75. Following the completion of the transaction, the chief executive officer now directly owns 157,353 shares in the company, valued at $13,244,402.01. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, CEO Michael A. Mussallem sold 19,875 shares of the business’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $84.17, for a total transaction of $1,672,878.75. Following the completion of the transaction, the chief executive officer now directly owns 157,353 shares in the company, valued at $13,244,402.01. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 6,725 shares of the business’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $85.00, for a total value of $571,625.00. Following the transaction, the vice president now owns 62,561 shares of the company’s stock, valued at $5,317,685. The disclosure for this sale can be found here. In the last three months, insiders have sold 94,525 shares of company stock worth $7,644,070. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $75.91 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.00 and a current ratio of 3.83. Edwards Lifesciences Co. has a 52-week low of $67.13 and a 52-week high of $131.73. The firm has a market cap of $46.93 billion, a price-to-earnings ratio of 32.72, a PEG ratio of 2.44 and a beta of 1.05. The business’s fifty day moving average is $80.53 and its 200 day moving average is $91.09.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. The Goldman Sachs Group dropped their price objective on Edwards Lifesciences from $97.00 to $73.00 and set a “neutral” rating on the stock in a research note on Thursday, November 3rd. Canaccord Genuity Group dropped their price target on Edwards Lifesciences from $106.00 to $91.00 and set a “hold” rating on the stock in a research note on Friday, October 14th. Deutsche Bank Aktiengesellschaft dropped their price target on Edwards Lifesciences from $113.00 to $83.00 in a research note on Friday, October 28th. Cowen dropped their price target on Edwards Lifesciences from $125.00 to $100.00 in a research note on Friday, October 28th. Finally, Wells Fargo & Company dropped their price target on Edwards Lifesciences from $121.00 to $93.00 and set an “overweight” rating on the stock in a research note on Friday, October 28th. Five equities research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.28.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

See Also

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWGet Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.